Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial
Merck & Co. Inc. (MRK) and Eisai Co. Ltd. (ESALF) said Friday that a late-stage trial of Merck's blockbuster cancer treatment Keytruda in combination with Eisai's drug Lenvima failed to meet its primary goals for treatment of certain types of endometrial cancer. The combo therapy did not sufficiently improve overall survival or progression-free survival, compared with a chemotherapy that is the current standard of care, the companies said. Merck and Eisai will continue to research the combination therapy in patients with other types of hard-to-treat cancers, Dr. Gregory Lubiniecki, vice president of global clinical development at Merck Research Laboratories, said in a statement. The Keytruda and Lenvima combination is already approved in the U.S. and other countries for treatment of certain types of advanced endometrial cancer and advanced renal cell cancer. Merck and Eisai shares were both little changed premarket on Friday. Merck shares have dropped 6.4% in the year to date, while Eisai shares are down 21%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-08-23 0756ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued